 |
|
| |
 |
A concise review of the relevant journal literature on topics specific to the diagnosis and treatment of patients presenting with hematologic malignancies
|
| |
Authored and peer-reviewed by an expert panel of Hematology and Oncology Specialists |
| |
6 bi-monthly newsletter issues and 6 podcasts (clinical practice case-study scenarios) |
| |
Delivered directly to your email in-box |
| |
Fully accredited – earn your CE credits online |
| |
Provided completely without charge or prerequisites |
|
|
| |
Chronic myelogenous leukemia
|
| |
Multiple Myeloma |
|
Aggressive Lymphoma |
|
Indolent lymphoma / CLL |
|
Myeloproliferative disorders |
|
Myelodysplastic Syndromes (MDS) |
At the conclusion of this activity,
participants should be able to: |
|
Identify treatment regimens appropriate for patients who are refractory or intolerant to standard agents
|
| |
Describe the current thinking on tailoring treatment based on new prognostic factors |
| |
Explain the new concepts involving the etiology and pathogenesis of these malignancies |
| |
Review state-of-the-art management of acute and chronic leukemias, lymphomas, myeloma and MDS |
|
Discuss the efficacy and toxicity profiles of FDA-approved and novel investigational therapeutic agents |
|
Summarize the scientific rationale for common combination regimens |
| |
|
| |
| |
Each month's issue is written by guest authors with expertise in the specific topic. The program is peer-reviewed by expert
program directors
|
| |
| |
For each issue, participants have the option of earning 1.0 AMA PRA Category1 Credit(s)™ or 1.0 contact hour per newsletter and 0.5 per podcast by reading the content, completing the post-test with a passing grade, and completing the evaluation. Certificates are provided, electronically, from the Johns Hopkins School of Medicine and The Institute for Johns Hopkins Nursing. For more information click
here. |
|
| |
|
|
